伏环孢素对免疫功能低下肾脏病患者SARS-CoV-2的抗病毒作用
本研究探讨伏环孢素在免疫功能低下肾脏病患者中对SARS-CoV-2的潜在抗病毒效果,包括20例肾移植受者的前瞻性随机开放标签概念验证研究,以及216例狼疮肾炎患者的事后分析,结果显示伏环孢素组病毒清除时间与他克莫司组无差异,但血药浓度达标时病毒载量下降更显著。
要点
- 伏环孢素组与他克莫司组SARS-CoV-2病毒清除时间无差异(中位12天)。
- 伏环孢素谷浓度达标时病毒载量下降幅度显著大于他克莫司组(ΔCt 7.7 vs 2.7,P=0.035)。
- 狼疮肾炎患者中伏环孢素暴露组SARS-CoV-2感染率6%,安慰剂组12%(RR 1.4 [0.97-2.06])。
核心结论
- 伏环孢素在免疫功能低下合并SARS-CoV-2感染患者中显示潜在正向风险-获益特征。
研究设计与样本
- 前瞻性随机开放标签概念验证研究纳入20例接受他克莫司为基础免疫抑制的肾移植受者,随机继续他克莫司或转换为伏环孢素。
- 对216例接受标准免疫抑制的狼疮肾炎患者进行事后分析,这些患者在一项临床试验中随机暴露于伏环孢素或安慰剂。
主要发现
- 肾移植受者中,伏环孢素组SARS-CoV-2病毒载量清除中位12天(IQR 8-28),他克莫司组中位12天(IQR 4-16),临床恢复无差异。
- 伏环孢素谷浓度达标时,SARS-CoV-2病毒载量下降ΔCt 7.7(3.4-10.7),显著大于他克莫司组的ΔCt 2.7(2.0-4.3),P=0.035。
- 狼疮肾炎患者中,伏环孢素暴露组SARS-CoV-2感染检出率6%(7/116),安慰剂组12%(12/100),相对风险1.4(0.97-2.06)。
- 伏环孢素暴露的狼疮肾炎患者无死于重症SARS-CoV-2感染,安慰剂组为3%(3/100),相对风险2.2(1.90-2.54)。
临床怎么用
- 对于免疫功能低下的肾脏病患者,伏环孢素可能作为兼顾免疫抑制与抗SARS-CoV-2的潜在选择,但需进一步研究确认。
局限性
- 概念验证研究样本量小(20例肾移植受者),狼疮肾炎分析为事后分析。
- 伏环孢素的抗病毒获益仅在谷浓度达标时观察到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunocompromised kidney patients are at increased risk of prolonged SARS-CoV-2 infection and related complications. Preclinical evidence demonstrates a more potent inhibitory effect of voclosporin on SARS-CoV-2 replication than tacrolimus in vitro. We investigated the potential antiviral effects of voclosporin on SARS-CoV-2 in immunocompromised patients. METHODS: First, we conducted a prospective, randomized, open-label, proof-of-concept study in 20 kidney transplant recipients (KTRs) on tacrolimus-based immunosuppression who contracted mild to moderate SARS-CoV-2 infection. Patients were randomized to continue tacrolimus or switch to voclosporin. Second, we performed a post hoc analysis on SARS-CoV-2 infections in 216 patients with lupus nephritis (LN) on standard immunosuppression who were randomly exposed to voclosporin or placebo as part of a clinical trial that was conducted during the worldwide COVID-19 pandemic. RESULTS: The primary end point was clearance of SARS-CoV-2 viral load and that did not differ between voclosporin-treated KTRs (median 12 days, interquartile range [IQR] 8-28) and tacrolimus-treated KTRs (median 12 days, IQR 4-16) nor was there a difference in clinical recovery. Pharmacokinetic analyses demonstrated that, when voclosporin trough levels were on-target, SARS-CoV-2 viral load dropped significantly more (ΔCt 7.7 [3.4-10.7]) compared to tacrolimus-treated KTRs (ΔCt 2.7 [2.0-4.3]; P = 0.035). In voclosporin-exposed patients with LN, SARS-CoV-2 infection was detected in 6% (7/116) compared to 12% (12/100) in placebo-exposed patients (relative risk [RR] 1.4 [0.97-2.06]). Notably, no voclosporin-exposed patients with LN died from severe SARS-CoV-2 infection compared to 3% (3/100) in placebo-exposed patients (RR 2.2 [1.90-2.54]). CONCLUSION: This proof-of-concept study shows a potential positive risk-benefit profile for voclosporin in immunocompromised patients with SARS-CoV-2 infection. These results warrant further investigations on voclosporin to establish an equipoise between infection and maintenance immunosuppression.
引用
- Arends EJ, Meziyerh S, Moes DJAR, et al. Voclosporin and the Antiviral Effect Against SARS-CoV-2 in Immunocompromised Kidney Patients. Kidney Int Rep. 2023. PMID: 38106593. doi:10.1016/j.ekir.2023.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。